| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2022 | 70.6% | Goldman Sachs | $15 → $13 | Maintains | Neutral |
| 08/12/2022 | 57.48% | Morgan Stanley | $11 → $12 | Maintains | Overweight |
| 05/12/2022 | 44.36% | Morgan Stanley | $18 → $11 | Maintains | Overweight |
| 03/21/2022 | 123.1% | Goldman Sachs | $19 → $17 | Maintains | Neutral |
| 03/15/2022 | 293.7% | Craig-Hallum | → $30 | Initiates Coverage On | → Buy |
| 03/11/2022 | 136.22% | Morgan Stanley | $20 → $18 | Maintains | Overweight |
| 11/15/2021 | 162.47% | Morgan Stanley | → $20 | Reinstates | → Overweight |
| 07/01/2021 | 149.34% | Goldman Sachs | $20 → $19 | Downgrades | Buy → Neutral |
| 04/19/2021 | 149.34% | Morgan Stanley | $18 → $19 | Maintains | Overweight |
| 03/08/2021 | 201.84% | Canaccord Genuity | → $23 | Initiates Coverage On | → Buy |
| 03/08/2021 | 136.22% | Morgan Stanley | → $18 | Initiates Coverage On | → Overweight |
| 03/08/2021 | 123.1% | JP Morgan | → $17 | Initiates Coverage On | → Overweight |
| 03/08/2021 | 149.34% | Goldman Sachs | → $19 | Initiates Coverage On | → Buy |
Bioventus Questions & Answers
The latest price target for Bioventus (NASDAQ: BVS) was reported by Goldman Sachs on September 7, 2022. The analyst firm set a price target for $13.00 expecting BVS to rise to within 12 months (a possible 70.60% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Bioventus (NASDAQ: BVS) was provided by Goldman Sachs, and Bioventus maintained their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioventus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioventus was filed on September 7, 2022 so you should expect the next rating to be made available sometime around September 7, 2023.
While ratings are subjective and will change, the latest Bioventus (BVS) rating was a maintained with a price target of $15.00 to $13.00. The current price Bioventus (BVS) is trading at is $7.62, which is out of the analyst's predicted range.